Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PEPGthis companyPepGen Inc.	$2.40	-3.07×	1.86×	0×	-2.62×	-57.5%	0.0%	0.0%	0.0%	-60.8%	-56.9%	-29.8%	0.12×	0.49×	0×	11.94×	0.0%	2	-0.15	2	C+
ALECAlector, Inc.	$2.49	-1.12×	5.24×	7.63×	-0.99×	-107.1%	54.1%	-692.8%	-679.2%	-466.3%	-62.5%	-114.6%	1.18×	0.22×	0×	3.83×	0.0%	4	-0.75	4	A
CRBPCorbus Pharmaceuticals Holdings, Inc.	$3.61	-1.38×	0.73×	0×	-1.04×	-45.8%	0.0%	0.0%	0.0%	-53.2%	-57.2%	-59.5%	0.01×	0.34×	0×	8.07×	0.0%	1	-7.01	2	B-
CRDFCardiff Oncology, Inc.	$0.80	-4.07×	4.14×	316.73×	-3.81×	-95.9%	100.0%	-8256.3%	-7732.0%	-101.0%	-105.9%	-20.2%	0.02×	0.37×	0×	3.67×	0.0%	2	-16.24	2	C
ELTXElicio Therapeutics, Inc.	$1.69	-3.09×	74.5×	0×	-3.16×	-86.9%	0.0%	0.0%	0.0%	-2418.8%	-201.0%	-30.3%	8.87×	0.11×	-33.29×	2.38×	0.0%	2	-11.04	2	C
FATEFate Therapeutics, Inc.	$1.95	-0.85×	0.56×	17.56×	-1.16×	-122.3%	-94.1%	-2222.4%	-2051.1%	-65.8%	-51.4%	-96.0%	0.38×	-0.25×	0×	5.79×	0.0%	2	-9.43	1	C-
Peer median	—	-1.38×	4.14×	7.63×	-1.16×	-95.9%	0.0%	-692.8%	-679.2%	-101.0%	-62.5%	-59.5%	0.38×	0.22×	0×	3.83×	0.0%	2	-9.43	2	—